Gene · 10666
Papers4,079
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 4,079
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Reprogramming the immunosuppressive breast cancer microenvironment: integrating cellular, metabolic, and stromal targets for rational immunotherapy. | Front Immunol | 2026 | 41766877 | PubTator, text mining | PubMed |
| A novel GMP-manufactured medicinal product candidate composed of NK and γδ T cells as adjunct immunotherapy for hematopoietic stem cell transplantation. | Cell Transplant | 2026 | 41761987 | PubTator, text mining | PubMed |
| Natural Killer Cell Phenotype and Function as a Predictive Factor for Treatment Response to Neoadjuvant Therapy in Breast Cancer Patients. | Int J Mol Sci | 2026 | 41751774 | PubTator, text mining | PubMed |
| Molecular Pathogenesis and Targeted Treatment of Richter Transformation. | Biomedicines | 2026 | 41751246 | PubTator, text mining | PubMed |
| Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives. | Vaccines (Basel) | 2026 | 41746109 | PubTator, text mining | PubMed |
| Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors. | Cells | 2026 | 41744817 | PubTator, text mining | PubMed |
| Nanotechnology-Driven Precision Modulation of Transplant Immunity: From Mechanistic Insights to Clinical Tolerance. | Int J Nanomedicine | 2026 | 41743232 | PubTator, text mining | PubMed |
| Natural killer cell-inspired dendritic mesoporous rare-earth nanoparticles potentiate X-ray-triggered reactive oxygen generation for low-dose radiotherapy-radiodynamic therapy. | Bioact Mater | 2026 | 41737643 | PubTator, text mining | PubMed |
| Editorial: Regulators of the immune-tumor microenvironment: a new frontier for cancer immunotherapy. | Front Med (Lausanne) | 2026 | 41737407 | PubTator, text mining | PubMed |
| Proliferative double-negative T (DNT)-cell responses to PD-1 blockade therapy were positively correlated with good clinical outcomes in non-small cell lung cancer patients. | Pak J Med Sci | 2026 | 41737188 | PubTator, text mining | PubMed |
| Feeder-free ex vivo expansion of cord blood-derived natural killer cells for enhanced proliferation and functional maturation. | Sci Rep | 2026 | 41735442 | PubTator, text mining | PubMed |
| Specific depletion of TIGIThigh CD226- clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. | J Immunother Cancer | 2026 | 41735000 | PubTator, text mining | PubMed |
| Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer. | J Immunother Cancer | 2026 | 41734998 | PubTator, text mining | PubMed |
| Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors and evades HLA I-driven inhibition. | J Immunother Cancer | 2026 | 41734996 | PubTator, text mining | PubMed |
| The tumor microenvironment in leukemia: molecular pathways of immune evasion. | Front Immunol | 2026 | 41727472 | PubTator, text mining | PubMed |
| Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays. | Front Immunol | 2026 | 41727470 | PubTator, text mining | PubMed |
| The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications. | Front Immunol | 2026 | 41727427 | PubTator, text mining | PubMed |
| High PVR protein expression marks clear cell renal cell carcinoma with metastatic spread. | Front Immunol | 2026 | 41727425 | PubTator, text mining | PubMed |
| Whole blood gene expression moderates associations between AD biomarkers and cognitive decline in cognitively unimpaired older adults. | Alzheimers Dement | 2026 | 41724695 | PubTator, text mining | PubMed |
| Biomarkers and advances in AML-MRC: from bench to bedside. | Ann Hematol | 2026 | 41711916 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10666/papers?page=4